GVBL

GENOMIC VALLEY BIOTECH financials

Market cap
₹8 Cr

Quarterly results

Q1 FY27: revenue down 55.6%, net profit down 50.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue0 0 0 0 0 −57%0 −77%0 −85%0 −56%
EBITDA0 0 0 0 0 −100%0 −94%0 0 −33%
Net profit0 0 -0 0 0 −100%0 −94%-0 +88%0 −50%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −19.5% 1Y

₹25.0₹30.0₹35.0₹40.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹39.14 on 10 Sept 2025 → ₹31.5. High ₹39.14 (10 Sept 2025), low ₹21.85 (10 Dec 2025).

Financials, as filed

Revenue grew 26.0% a year over 2 years, FY24 to FY26. Operating margin narrowed to 14.8%.

Year endingFY24FY25FY26
Revenue₹0 Cr₹1 Cr₹0 Cr
Operating profit₹0 Cr₹0 Cr₹0 Cr
Operating margin17.6%50.6%14.8%
Interest₹0 Cr₹0 Cr₹0 Cr
Depreciation₹0 Cr₹0 Cr₹0 Cr
Net profit₹0 Cr₹0 Cr₹0 Cr
Net margin17.6%42.4%7.4%
Cash from operations₹-0 Cr₹0 Cr₹-0 Cr
Free cash flow₹-0 Cr₹0 Cr₹-0 Cr
ROCE0.6%11.8%1.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr
Reserves₹1 Cr₹-0 Cr₹0 Cr₹0 Cr₹1 Cr₹1 Cr
Borrowings₹2 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other liabilities₹2 Cr₹1 Cr₹1 Cr₹1 Cr₹0 Cr₹0 Cr
Total liabilities₹8 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr
Fixed assets₹6 Cr₹2 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹1 Cr₹2 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr
Total assets₹8 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters trimmed −0.66 pp while the public added +0.66 pp.

Promoters
46.1%
Public
53.9%

Since Jun 2025

  • Promoters −0.66 pp
  • Public +0.66 pp

How it drifted, 12 quarters

Over this window promoters fell from 66.3% to 46.1% — −20.3 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 66.3%, Public 33.7%.Dec '23: Promoters 65.0%, Public 35.0%.Mar '24: Promoters 64.2%, Public 35.8%.Jun '24: Promoters 64.1%, Public 35.9%.Sep '24: Promoters 54.7%, Public 45.3%.Dec '24: Promoters 46.8%, Public 53.2%.Mar '25: Promoters 46.8%, Public 53.2%.Jun '25: Promoters 46.7%, Public 53.3%.Sep '25: Promoters 46.7%, Public 53.3%.Dec '25: Promoters 46.1%, Public 53.9%.Mar '26: Promoters 46.1%, Public 53.9%.Jun '26: Promoters 46.1%, Public 53.9%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of GENOMIC VALLEY BIOTECH LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Yogesh Agrawal 46.06%unchanged
Deepti Aggarwal 11.00%unchanged
Amar Aggarwal 9.05%unchanged
Vikram Ashokkumar Jain 5.50%unchanged
Wasp Tradmart Private Limited 1.19%−0.06 pp
Ojaswini Avantika 0.00%unchanged
Parul Agarwal 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse GENOMIC VALLEY BIOTECH LIMITED

Guides on how to read this kind of business and the numbers that matter.